UBS Group
RPID icon

UBS Group’s Rapid Micro Biosystems RPID Stock Holding History

UBS Group’s Portfolio RPID Stock Details RPID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.5K Buy
11,252
+11,211
+27,344% +$41K ﹤0.01% 7780
2025
Q4 		$119 Sell
41
-249
-86% -$865 ﹤0.01% 10165
2025
Q3 		$969 Sell
290
-8,403
-97% -$26.6K ﹤0.01% 9478
2025
Q2 		$30K Buy
8,693
+8,672
+41,295% +$25.2K ﹤0.01% 8158
2025
Q1 		$55 Buy
+21
New +$48 ﹤0.01% 10002
2024
Q3 		– Sell
-98
Closed -$65 – 9984
2024
Q2 		$65 Sell
98
-148
-60% -$127 ﹤0.01% 9212
2024
Q1 		$239 Buy
+246
New +$239 ﹤0.01% 8698
2023
Q1 		– Sell
-593
Closed -$670 – 10262
2022
Q4 		$670 Sell
593
-1,468
-71% -$3.55K ﹤0.01% 10105
2022
Q3 		$6K Sell
2,061
-2,569
-55% -$9.97K ﹤0.01% 9056
2022
Q2 		$20K Sell
4,630
-316
-6% -$1.47K ﹤0.01% 6880
2022
Q1 		$34K Sell
4,946
-1,999
-29% -$14.7K ﹤0.01% 6877
2021
Q4 		$74K Buy
6,945
+6,407
+1,191% +$100K ﹤0.01% 6563
2021
Q3 		$10K Buy
+538
New +$11.1K ﹤0.01% 8010

Other funds holding RPID

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
AWGLSCP
ABG-WTT Global Life Science Capital Partners Central, Hong Kong, Hong Kong $12.3M AUM 3.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return
EFA
Evernest Financial Advisors Carmel, Indiana $481M AUM 19.97% 1-Year Est. Return
SEI Investments
SEI Investments Oaks, Pennsylvania $108B AUM 26.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group's RPID Position: Q1 2026 in Review

UBS Group increased its Rapid Micro Biosystems (RPID) stake by 27,344% in Q1 2026, buying an estimated $41K and bringing the position to 11,252 shares worth $25.5K. The position accounts for ﹤0.01% of the portfolio, ranked #7780.

UBS Group first reported a position in RPID in Q3 2021 and has held it in 13 quarters since. The position peaked at $74K in Q4 2021. 46 funds tracked by Wall St. Rank hold RPID as of Q1 2026.

  • UBS Group held 11,252 shares of Rapid Micro Biosystems worth $25.5K as of Q1 2026.
  • UBS Group bought 11,211 Rapid Micro Biosystems shares in Q1 2026, an estimated $41K.
  • Rapid Micro Biosystems made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7780 holding.
  • UBS Group first reported a position in Rapid Micro Biosystems in Q3 2021 and has held it in 13 quarters since.
  • UBS Group's Rapid Micro Biosystems position peaked at $74K in Q4 2021.
  • 46 funds tracked by Wall St. Rank held Rapid Micro Biosystems as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.